Morgan Stanley Maintains Overweight Rating for Elevance Health: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Morgan Stanley has maintained its Overweight rating for Elevance Health (NYSE:ELV) and increased its price target from $571.00 to $585.00. Elevance Health, a leading health insurer in the U.S., is unique as the largest single provider of Blue Cross Blue Shield branded coverage. The company's reach expands beyond 14 states through government-sponsored programs such as Medicaid and Medicare Advantage plans.
July 25, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley's maintained Overweight rating and increased price target for Elevance Health could potentially boost investor confidence and positively impact the company's stock price in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Morgan Stanley's decision to maintain an Overweight rating and raise the price target for Elevance Health indicates a positive outlook for the company, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100